106 related articles for article (PubMed ID: 6138791)
1. High doses of diazepam improve neuroleptic-resistant chronic schizophrenic patients.
Nestoros JN; Nair NP; Pulman JR; Schwartz G; Bloom D
Psychopharmacology (Berl); 1983; 81(1):42-7. PubMed ID: 6138791
[TBL] [Abstract][Full Text] [Related]
2. High dose diazepam in schizophrenia.
Beckmann H; Haas S
Psychopharmacology (Berl); 1980; 71(1):79-82. PubMed ID: 6779328
[TBL] [Abstract][Full Text] [Related]
3. Diazepam in high doses is effective in schizophrenia.
Nestoros JN; Suranyi-Cadotte BE; Spees RC; Schwartz G; Nair NP
Prog Neuropsychopharmacol Biol Psychiatry; 1982; 6(4-6):513-6. PubMed ID: 6891818
[TBL] [Abstract][Full Text] [Related]
4. Double-blind comparison of alprazolam, diazepam, and placebo for the treatment of negative schizophrenic symptoms.
Csernansky JG; Riney SJ; Lombrozo L; Overall JE; Hollister LE
Arch Gen Psychiatry; 1988 Jul; 45(7):655-9. PubMed ID: 3289523
[TBL] [Abstract][Full Text] [Related]
5. Effect of maprotiline combined with conventional neuroleptics against negative symptoms of chronic schizophrenia.
Yamagami S; Soejima K
Drugs Exp Clin Res; 1989; 15(4):171-6. PubMed ID: 2570687
[TBL] [Abstract][Full Text] [Related]
6. Systematic dosage reduction in treatment-resistant schizophrenic patients.
Van Putten T; Marshall BD; Liberman R; Mintz J; Kuehnel TG; Bowen L; Aravagiri M; Marder SR
Psychopharmacol Bull; 1993; 29(2):315-20. PubMed ID: 7904763
[TBL] [Abstract][Full Text] [Related]
7. The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group.
Kramer MS; Last B; Getson A; Reines SA
Arch Gen Psychiatry; 1997 Jun; 54(6):567-72. PubMed ID: 9193198
[TBL] [Abstract][Full Text] [Related]
8. High dose diazepam treatment and its effect on prolactin secretion in adolescent schizophrenic patients.
Weizman A; Tyano S; Wijsenbeek H; Ben David M
Psychopharmacology (Berl); 1984; 82(4):382-5. PubMed ID: 6427833
[TBL] [Abstract][Full Text] [Related]
9. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.
Small JG; Hirsch SR; Arvanitis LA; Miller BG; Link CG
Arch Gen Psychiatry; 1997 Jun; 54(6):549-57. PubMed ID: 9193196
[TBL] [Abstract][Full Text] [Related]
10. Responses to apomorphine, amphetamine, and neuroleptics in schizophrenic subjects.
Angrist B; Rotrosen J; Gershon S
Psychopharmacology (Berl); 1980 Jan; 67(1):31-8. PubMed ID: 6102776
[TBL] [Abstract][Full Text] [Related]
11. Cholecystokinin appears to have antipsychotic properties.
Nair NP; Bloom DM; Nestoros JN
Prog Neuropsychopharmacol Biol Psychiatry; 1982; 6(4-6):509-12. PubMed ID: 6891817
[TBL] [Abstract][Full Text] [Related]
12. Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale.
Harvey PD; Davidson M; White L; Keefe RS; Hirschowitz J; Mohs RC; Davis KL
Biol Psychiatry; 1996 Oct; 40(8):755-60. PubMed ID: 8894068
[TBL] [Abstract][Full Text] [Related]
13. [Antidepressive effect of pyridoxine (vitamin B6) in neuroleptic-treated schizophrenic patients with co-morbid minor depression--preliminary open-label trial].
Shiloh R; Weizman A; Weizer N; Dorfman-Etrog P; Munitz H
Harefuah; 2001 May; 140(5):369-73, 456. PubMed ID: 11419053
[TBL] [Abstract][Full Text] [Related]
14. The effect of neuroleptic treatment and of high dosage diazepam therapy on beta-endorphin immunoreactivity in plasma of schizophrenic patients.
Gramsch C; Emrich HM; John S; Haas S; Beckmann H; Zaudig M; von Zerssen D
J Neural Transm; 1984; 59(2):133-41. PubMed ID: 6144724
[TBL] [Abstract][Full Text] [Related]
15. [New chemotherapy approaches to psychoses].
Olié JP; Baylé FJ
Encephale; 1997 Apr; 23 Spec No 2():2-9. PubMed ID: 9273302
[TBL] [Abstract][Full Text] [Related]
16. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia.
Martín J; Gómez JC; García-Bernardo E; Cuesta M; Alvarez E; Gurpegui M
J Clin Psychiatry; 1997 Nov; 58(11):479-83. PubMed ID: 9413413
[TBL] [Abstract][Full Text] [Related]
17. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia.
Azorin JM; Spiegel R; Remington G; Vanelle JM; Péré JJ; Giguere M; Bourdeix I
Am J Psychiatry; 2001 Aug; 158(8):1305-13. PubMed ID: 11481167
[TBL] [Abstract][Full Text] [Related]
18. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group.
Bondolfi G; Dufour H; Patris M; May JP; Billeter U; Eap CB; Baumann P
Am J Psychiatry; 1998 Apr; 155(4):499-504. PubMed ID: 9545995
[TBL] [Abstract][Full Text] [Related]
19. Diazepam treatment of early signs of exacerbation in schizophrenia.
Carpenter WT; Buchanan RW; Kirkpatrick B; Breier AF
Am J Psychiatry; 1999 Feb; 156(2):299-303. PubMed ID: 9989567
[TBL] [Abstract][Full Text] [Related]
20. Phase-IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia. The RIS-CAN-3 Study Group.
Chouinard G; Kopala L; Labelle A; Beauclair L; Johnson SV; Singh KI
Can J Psychiatry; 1998 Dec; 43(10):1018-25. PubMed ID: 9868567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
